ArticleJournal of thrombosis and thrombolysis2026
Pulmonary embolism associated with CRBN-targeting immunomodulatory drugs: a FAERS-based pharmacovigilance and mechanistic analysis.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
CRBN-targeting immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, are widely used in hematologic malignancies but are associated with an elevated risk of venous thromboembolism (VTE). However, real-world risk patterns and the potential biological mechanisms underlying pulmonary embolism (PE) remain incompletely characterized. We conducted a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) from 2004 to Q3 2025. Disproportionality analyses (ROR, PRR, BCPNN, MGPS) and Weibull distribution modeling were employed to assess signal strength and time-to-onset (TTO). Systems biology tools, including network pharmacology and enrichment analyses (GO, KEGG), were used to uncover shared and drug-specific pathogenic pathways. Bibliometric mapping of core literature further validated mechanistic insights and policy relevance. A total of 2,428 and 372 PE cases were identified for lenalidomide and pomalidomide, respectively. Both drugs exhibited an "early failure" risk profile (β < 1), with a shorter median TTO for lenalidomide (81.5 days) compared to pomalidomide (134 days). High-risk subgroups included males, elderly patients (65-85 years), and individuals with obesity (> 100 kg). The PI3K-Akt pathway emerged as a central mechanism for endothelial dysfunction and thrombogenesis. Pomalidomide showed additional enrichment in fluid shear stress and TNF signaling pathways. Literature analysis confirmed alignment with core topics such as thrombotic events, platelet function, and prophylactic anticoagulation. Our findings highlight an urgent need to shift from empirical anticoagulation to precision-based thromboprophylaxis in patients treated with CRBN-targeting IMiDs. Early-onset PE risk is mechanistically linked to vascular endothelial injury and inflammatory signaling, supporting the use of dynamic risk stratification tools (e.g., IMPEDE-VTE score) and early DOAC intervention. Public health policy should integrate molecular insights with real-world surveillance to optimize clinical safety frameworks for oncology patients.
Indexed as
Identifiers
42176162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.